Patients with the *1/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.